Cherry Biotech
Harry Dawson is an experienced Scientific R&D Project Manager at Cherry Biotech, overseeing international collaborations and technology validation since May 2023. Prior roles include Industrial PhD Researcher in BioEngineering at MedinCell, where work focused on microfluidics for long-acting injectables, and research internships at Institut Curie and ESPCI Paris, contributing to high-throughput screening technologies and diagnostic devices, respectively. Previous experience in the medical device industry includes roles as a Sales Associate and Technical Representative at SRA Developments Ltd, and a Global Education Senior Peer Adviser at Keele University. Educational qualifications comprise a Master of Business Administration from IAE France, a Master's in Biomedical/Medical Engineering from Arts et Métiers, and a Bachelor of Science in Biological Sciences from Keele University, alongside ongoing studies in Biology at Western Sydney University.
This person is not in any teams
Cherry Biotech
Cherry Biotech is a biomedical technology (Organ on Chip) company that develops instruments for drug discovery and personalised medicine. Its mission is to replace animal testing by reconstructing human tissue (Organoids) in vitro for drug testing. Cherry Biotech's CUBIX platform enables pharmaceutical, biotech companies and healthcare providers to recreate immunocompetent human vascularized organ models and tumor microenvironments for better evaluation of their drug candidates. By enabling the reconstruction of human 3D models that mimic human physiology and pathophysiology over several weeks, Cherry Biotech's proprietary CUBIX technology is the only solution that can convert a standard 2D multi-well plate into a 3D cell culture (Organ on Well). This innovative patented technology allows for the implementation of the current regulatory change on the ethics of animal experimentation while remaining compatible with the current industry workflow.